Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The More Life CompanySTU:20MP -2.70% Debt-to-Equity is -2.89 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 810 Drug Manufacturers companies, The More Life Company ranks worse than 123456.67% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for The More Life Company's Debt-to-Equity or its related term are showing as below:
STU:20MP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.88 Med: 0 Max: 0.05
Current: -2.88
During the past 7 years, the highest Debt-to-Equity Ratio of The More Life Company was 0.05. The lowest was -2.88. And the median was 0.00.
STU:20MP's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28
vs STU:20MP: -2.88
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
The More Life Company Debt-to-Equity Related Terms
The More Life Company Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for The More Life Company's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, The More Life Company's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The More Life Company Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The More Life Company's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where The More Life Company's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The More Life Company (STU:20MP) has a Debt-to-Equity of -2.89 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The More Life Company and its competitors. According to the industry distribution chart, The More Life Company ranks #999999 out of 810 companies in the Drug Manufacturers industry.
Is The More Life Company's Debt-to-Equity too high?
The More Life Company's current Debt-to-Equity is -2.89. Based on the distribution chart, The More Life Company ranks #999999 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does The More Life Company's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, The More Life Company ranks #999999 out of 810 companies for Debt-to-Equity. This places The More Life Company in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The More Life Company and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The More Life Company's current Debt-to-Equity is -2.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (STU:20MP) has a current Debt-to-Equity of -2.89. The current Debt-to-Equity is -2.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For The More Life Company (STU:20MP), the current Debt-to-Equity is -2.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20MP has been successfully added to your 
